
Masson’s trichrome staining: the cell nuclei are blue-black, the cytoplasms (cell bodies) are mauve and the collagen fibers are green.
Credit: Riccardo Di Corato – laboratoire MSC (CNRS/Université Paris Diderot)
By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by external physical stimuli (a magnetic field and light), scientists obtained total tumor regression in mice.
Non-toxic when they are not activated, such therapies can also achieve a reduction in adverse effects. These results demonstrate the importance of multiple treatments.
One of the strategies employed to limit the adverse effects of cancer therapies is the development of nanocarrier systems that can convey active ingredients to target tumor cells. These are referred to as “physical” therapies when the active substances, molecules or nanoparticles, can be remotely activated by external physical stimuli — in this case by light or a magnetic field. In this context, the study team developed a new type of carrier that combines photosensitivity and magnetism. To achieve this, they first encapsulated magnetic nanoparticles in the inner compartment of a liposome in sufficient quantities to render it ultra-magnetic, before incorporating photosensitizers into its lipid bilayer, while preserving an optimum size for circulation in the blood.
These liposomes, containing magnetic nanoparticles and photosensitizers, were injected directly into the tumor in the mouse model. The scientists thus combined two techniques to achieve complete destruction of cancer cells. The first one, magnetic hyperthermia, consists in exciting the nanoparticles with a magnetic field to raise the temperature of the tumor and destroy it.. The second method, photodynamic therapy, is made possible by the photosensitizers, which, when activated, release reactive oxygen species that are toxic to tumor cells. These two physical therapies act in synergy on the activity of the proteins involved in apoptosis, or programmed cell death. Their combination thus induces total regression of the tumor, while a single therapy is not able to stop its growth.
Read more: Combining magnetism and light to fight cancer
The Latest on: Tumor regression
[google_news title=”” keyword=”Tumor regression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Tumor regression
- Alcohol consumption likely to continue, despite harms and parallels with tobacco, Carl Erik Fisher predictson June 7, 2023 at 12:00 pm
Australians aren't drinking like we used to. Yet, despite parallels to tobacco use, some experts say alcohol's history and place in society mean it'll remain indefinitely.
- Why TransCode Therapeutics Stock Is Trading Higher Premarket Todayon June 7, 2023 at 6:00 am
TransCode Therapeutics Inc (NASDAQ: RNAZ) announced acceptance for publication by Frontiers in Molecular Biosciences of a preclinical study using TransCode's lead therapeutic candidate, TTX-MC138, in ...
- New Tool Improves Detection of Cervical Precancerous Lesionson June 7, 2023 at 12:56 am
Recently, scientists developed a new technology for early screening and monitoring of cervical precancerous lesions.
- Researchers develop new technology for early detection of precancerous cervical lesionson June 6, 2023 at 12:27 pm
Professor Yang Wulin's research group from the Institute of Health and Medical Technology, Hefei Institute of Physical Sciences of Chinese Academy of Sciences has developed a new technology for early ...
- Omitting RT Safe in Many Locally Advanced Rectal Cancerson June 5, 2023 at 4:13 pm
If tumor regression was less than 20%, pelvic chemoradiotherapy was given prior to total mesorectal excision. Those unable to complete at least five FOLFOX cycles were given chemoradiotherapy, and it ...
- Changes in RECIST tumor measures correlate linearly with survival in patients treated with checkpoint inhibitorson June 3, 2023 at 11:04 am
The Response Evaluation Criteria In Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories ...
- FDA's cancer chief weighs in on common chemo shortages — reporton May 31, 2023 at 12:41 pm
Richard Pazdur, director of the FDA’s Oncology Center of Excellence, attributes the current shortage of two cancer drugs to drug companies that haven't invested in building out their production ...
- Biotheryx to Present New Preclinical Data on Bifunctional Degraders for CDK4/6 and SOS1 at 2023 ASCO Annual Meetingon May 25, 2023 at 2:14 pm
BTX-9341 demonstrated potent degradation of CDK4/6 and tumor growth regression in resistant cells in preclinical breast cancer models, along with robust blood brain barrier penetration SOS1 ...
- Jeff Bridges' cancer tumor significantly reduced, COVID battle continueson May 25, 2023 at 10:51 am
In a candid interview with AARP, Hollywood actor Jeff Bridges provides an insightful update on his health, sharing positive news about the significant shrinkage of his tumor while ...
- Carina Biotech to Participate in Three Upcoming Conferenceson May 24, 2023 at 3:00 pm
Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced that the management team will participate in the three upcoming conferences as ...
via Bing News